The story focuses on a team at the Mayo Clinic who have been delivering obesity care by phenotype since 2016.
Some consider them pioneers in obesity precision medicine.
Others aren't so sure -- and want to see a rigorous randomized control trial testing their work.
Here's something everyone seems to agree on: For targeted obesity therapies to become mainstream, clinicians need to arrive at a consensus about how to subtype patients.